Save Product
Product Details
Synonyms
FCGR3A, CD16A, FCG3, FCGR3, IGFR3
Source
Human CD16a (V176), His Tag (CD8-H52H4) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1 (F176V)).
Predicted N-terminus: Gly 17
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.7 kDa. The protein migrates as 40-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human CD16a (V176), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) is more than 95% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Report
Bioactivity-SPR
Immobilized Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) on CM5 Chip via anti-His antibody, can bind Monoclonal Anti-Her2 Antibody, Human IgG1 (Cat. No. HE2-M598) with an affinity constant of 0.441μM as determined in SPR assay (Biacore T200) (QC tested).
Protocol
Herceptin captured on Protein A Chip can bind Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) with an affinity constant of 0.124 μM as determined in SPR assay (Biacore 8K) (Routinely tested).
Protocol
Herceptin immobilized on CM5 Chip can bind Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) with an affinity constant of 0.215 μM as determined in SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) on HIS1K Biosensor, can bind Herceptin with an affinity constant of 0.447 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Herceptin on Protein A Biosensor, can bind Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) with an affinity constant of 0.37 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Herceptin on FAB2G Biosensor, can bind Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) with an affinity constant of 0.31 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
Recent Advances
Drug Development Progress- English Name：
Low affinity immunoglobulin gamma Fc region receptor III-A
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
14 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
Drug Candidate Licensing
